OR WAIT null SECS
Growth and Advancements in Fill/Finish
Employing novel technologies and more patient-centric approaches
Delving into Biopharmaceutical Development and Manufacturing
Quality Considerations in Changing Excipient Providers
May 26, 2022
Lonza and Israel Biotech Fund form a two-year agreement to support accelerated development and manufacture of biologics and small molecules.
AGC Biologics is investing in viral vector suspension technology at its new Longmont, Colo., facility.
Lubrizol has launched Apisolex technology to improve solubility and simplify the manufacturing of parenteral drug products.
May 24, 2022
AbbVie and Cugene have reached an exclusive license option agreement for CUG252, Cugene’s lead therapeutic candidate.
Sferalp will use Fluid Air’s PolarDry technology for powder processing.
A new initiative aims to speed the approval of and access to new drugs for young patients around the world, while limiting the number of children needed for testing in clinical trials.
AstraZeneca's recombinant COVID-19 vaccine, originally invented by the University of Oxford, has been approved as a third dose booster vaccine in the EU.
EMA has recommended the marketing authorization of Xenpozyme (olipudase alfa) in the European Union.
Investment has been made into a new science hub at the University of Edinburgh for the development of treatments for lung infections and future pandemics.
May 23, 2022
AstraZeneca has signed a license agreement with RQ Biotechnology for monoclonal antibodies to treat COVID-19.